Akoya Biosciences, Inc. — Operating Income by Fiscal Year
5 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/137a56c5-1853-4115-991f-383a11524536/serie/operating-income
| Fiscal year | Operating Income | Period | Evidence |
|---|---|---|---|
| FY 2024 | $-46.7M | 2024-01-01 – 2024-12-31 | evidence 0001558370-25-003124 |
| FY 2023 | $-57.7M | 2023-01-01 – 2023-12-31 | evidence 0001558370-24-002380 |
| FY 2022 | $-66.1M | 2022-01-01 – 2022-12-31 | evidence 0001558370-23-002954 |
| FY 2021 | $-39.3M | 2021-01-01 – 2021-12-31 | evidence 0001558370-22-003581 |
| FY 2020 | $-12.0M | 2020-01-01 – 2020-12-31 | evidence 0001558370-22-003581 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).